应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
ABBV 艾伯维公司
休市中 06-05 16:00:00 EDT
227.23
+2.29
+1.02%
盘后
226.60
-0.63
-0.28%
19:59 EDT
最高
230.47
最低
226.00
成交量
624.89万
今开
227.37
昨收
224.94
日振幅
1.99%
总市值
4,016亿
流通市值
4,006亿
总股本
17.67亿
成交额
14.26亿
换手率
0.35%
流通股本
17.63亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜艾伯维公司盘中上涨3.09%，投行上调目标价叠加多项药物获批
行情直击 · 06-05 01:51
异动解读｜艾伯维公司盘中上涨3.09%，投行上调目标价叠加多项药物获批
艾伯维宣布Venclyxto® (Venetoclax)获欧盟委员会批准扩大标签，纳入先前未经治疗的慢性淋巴细胞白血病新组合方案
美股速递 · 05-29
艾伯维宣布Venclyxto® (Venetoclax)获欧盟委员会批准扩大标签，纳入先前未经治疗的慢性淋巴细胞白血病新组合方案
艾伯维(ABBV.US)CD123 ADC获批上市
智通财经 · 05-28
艾伯维(ABBV.US)CD123 ADC获批上市
FDA：Pivekimab Sunirine-Pvzy处方信息新增黑框警告，提示肝毒性风险，包括肝窦阻塞综合征
美股速递 · 05-28
FDA：Pivekimab Sunirine-Pvzy处方信息新增黑框警告，提示肝毒性风险，包括肝窦阻塞综合征
FDA批准Pivekimab Sunirine-Pvzy用于治疗超罕见血液恶性肿瘤——母细胞性浆细胞样树突状细胞肿瘤
美股速递 · 05-28
FDA批准Pivekimab Sunirine-Pvzy用于治疗超罕见血液恶性肿瘤——母细胞性浆细胞样树突状细胞肿瘤
艾伯维宣布Maviret® (格卡瑞韦/哌仑他韦) 获CHMP积极意见 用于治疗急性丙型肝炎感染
美股速递 · 05-22
艾伯维宣布Maviret® (格卡瑞韦/哌仑他韦) 获CHMP积极意见 用于治疗急性丙型肝炎感染
艾伯维旗下爱力根美学获CHMP积极意见：Boey®有望改善成人中重度眉间纹
美股速递 · 05-22
艾伯维旗下爱力根美学获CHMP积极意见：Boey®有望改善成人中重度眉间纹
阿布扎比主权基金大幅减持西维斯健康股份，持股量骤降逾六成
美股速递 · 05-15
阿布扎比主权基金大幅减持西维斯健康股份，持股量骤降逾六成
今年投资者纷纷涌入高股息股，这些标的位列华尔街买入名单
老虎资讯综合 · 05-12
今年投资者纷纷涌入高股息股，这些标的位列华尔街买入名单
艾伯维(ABBV.US)乌帕替尼斑秃适应症已向美国FDA递交上市申请
智通财经 · 04-29
艾伯维(ABBV.US)乌帕替尼斑秃适应症已向美国FDA递交上市申请
艾伯维向FDA提交乌帕替尼治疗重度斑秃成人与青少年患者的新适应症申请
美股速递 · 04-28
艾伯维向FDA提交乌帕替尼治疗重度斑秃成人与青少年患者的新适应症申请
艾伯维Rinvoq在12周疗效评估中展现优于Humira的低疾病活动度和缓解率
美股速递 · 04-28
艾伯维Rinvoq在12周疗效评估中展现优于Humira的低疾病活动度和缓解率
Evolveimmune Therapeutics达成临床前里程碑 触发艾伯维1800万美元付款
美股速递 · 04-28
Evolveimmune Therapeutics达成临床前里程碑 触发艾伯维1800万美元付款
Evolveimmune Therapeutics与艾伯维合作达成临床前研究里程碑
美股速递 · 04-28
Evolveimmune Therapeutics与艾伯维合作达成临床前研究里程碑
Rinvoq® (乌帕替尼) 在对首个TNF抑制剂应答不佳的类风湿关节炎患者头对头研究中，主要终点指标表现优于Humira® (阿达木单抗)
美股速递 · 04-28
Rinvoq® (乌帕替尼) 在对首个TNF抑制剂应答不佳的类风湿关节炎患者头对头研究中，主要终点指标表现优于Humira® (阿达木单抗)
艾伯维向FDA提交Skyrizi®用于中重度活动性克罗恩病成人患者皮下诱导治疗的监管申请
美股速递 · 04-27
艾伯维向FDA提交Skyrizi®用于中重度活动性克罗恩病成人患者皮下诱导治疗的监管申请
财报前瞻｜艾伯维公司本季度营收预计增13.93%，机构观点偏空
财报Agent · 04-22
财报前瞻｜艾伯维公司本季度营收预计增13.93%，机构观点偏空
Collplant计划开发新型再生真皮与软组织填充剂产品组合，目标两年内启动临床试验
美股速递 · 04-13
Collplant计划开发新型再生真皮与软组织填充剂产品组合，目标两年内启动临床试验
艾尔建工业公司行使权利终止与Collplant Biotechnologies Ltd的开发协议
美股速递 · 04-13
艾尔建工业公司行使权利终止与Collplant Biotechnologies Ltd的开发协议
海思科将获3000万美元首付款，潜在里程碑付款最高可达7.15亿美元
美股速递 · 04-12
海思科将获3000万美元首付款，潜在里程碑付款最高可达7.15亿美元
加载更多
公司概况
公司名称：
艾伯维公司
所属市场：
NYSE
上市日期：
--
主营业务：
艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。
发行价格：
--
{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":227.23,"timestamp":1780689600000,"preClose":224.94,"halted":0,"volume":6248888,"hourTrading":{"tag":"盘后","latestPrice":226.6,"preClose":227.23,"latestTime":"19:59 EDT","volume":382992,"amount":87025490.3039,"timestamp":1780703975060,"change":-0.63,"changeRate":-0.002773,"amplitude":0.008461},"delay":0,"changeRate":0.010180492575797956,"floatShares":1762950764,"shares":1767384632,"eps":2.030053,"marketStatus":"休市中","change":2.29,"latestTime":"06-05 16:00:00 EDT","open":227.37,"high":230.47,"low":226,"amount":1425842893.88848,"amplitude":0.019872,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.030053,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1780905600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":224.94,"dividendRate":0.029662,"preHourTrading":{"tag":"盘前","latestPrice":227.4155,"preClose":224.94,"latestTime":"09:29 EDT","volume":5469,"amount":1234243.92,"timestamp":1780666189842,"change":2.4755,"changeRate":0.011005,"amplitude":0.035671},"postHourTrading":{"tag":"盘后","latestPrice":226.6,"preClose":227.23,"latestTime":"19:59 EDT","volume":382992,"amount":87025490.3039,"timestamp":1780703975060,"change":-0.63,"changeRate":-0.002773,"amplitude":0.008461},"volumeRatio":1.014741474863069,"optionData":{"bulkOrders":[{"symbol":"ABBV","call":false,"expireDate":1781755200000,"strike":"185.0","timestamp":1780684309171,"price":0.1,"volume":3814,"amount":38140,"type":"-"}]},"impliedVol":0.2768,"impliedVolPercentile":0.4661},"requestUrl":"/m/hq/s/abbv","defaultTab":"news","newsList":[{"id":"1185099131","title":"异动解读｜艾伯维公司盘中上涨3.09%，投行上调目标价叠加多项药物获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1185099131","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185099131?lang=zh_cn&edition=full","pubTime":"2026-06-05 01:51","pubTimestamp":1780595477,"startTime":"0","endTime":"0","summary":"6月5日，艾伯维公司盘中上涨3.09%，报223.85美元/股，成交额7.55亿美元。消息面上，Rothschild&Co Redburn于6月4日将艾伯维目标价从265美元上调至284美元，维持买入评级。据FactSet数据，分析师对艾伯维平均评级为\"超配\"，平均目标价253.85美元。多重利好共振推动股价走高。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153825148","title":"艾伯维宣布Venclyxto® (Venetoclax)获欧盟委员会批准扩大标签，纳入先前未经治疗的慢性淋巴细胞白血病新组合方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1153825148","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153825148?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:01","pubTimestamp":1780056085,"startTime":"0","endTime":"0","summary":"艾伯维公司宣布，其药物Venclyxto® (Venetoclax)已获得欧洲委员会的授权，可扩展其标签适应症。此次批准允许将Venclyxto与额外的治疗方案组合，用于先前未经治疗的慢性淋巴细胞白血病患者。这一决定为患者提供了新的治疗选择，并可能改变该疾病的一线治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","IE0009355771.USD","LU0124676726.USD","LU1267930573.SGD","ABBV","LU0203347892.USD","LU2133065610.SGD","SG9999001440.SGD","IE000SO60NU8.SGD","LU0949170772.SGD","LU0868494708.USD","SG9999003800.SGD","SG9999011175.SGD","LU1093756325.SGD","SG9999015952.SGD","IE00BFTCPJ56.SGD","LU0820561818.USD","LU0985320562.USD","LU0820561909.HKD","IE00BDGV0183.EUR","LU0234570918.USD","IE0002270589.USD","LU2023251221.USD","LU2129689431.USD","LU0689472784.USD","LU0661504455.SGD","LU0456855351.SGD","IE000F7OJYX1.SGD","LU1732800096.USD","LU0417517546.SGD","LU2237443382.USD","LU1929549753.HKD","LU0029864427.USD","BK4588","BK4559","BK4550","LU0098860793.USD","LU2087621335.USD","LU1496350502.SGD","LU0553294199.USD","IE00B3PB1722.GBP","SG9999015978.USD","LU0738911758.USD","LU0965509101.SGD","LU1934455277.USD","LU1989772840.SGD","LU0965509010.AUD","LU1718418525.SGD","SG9999015986.USD","LU0708994859.HKD","LU0320765646.SGD","LU1037948541.HKD","LU2089984988.USD","LU1732799900.SGD","LU1934455863.HKD","LU2237443549.SGD","LU1983299246.USD","LU0069063385.USD","LU1551013342.USD","IE00BGHQF631.EUR","LU0859254822.USD","IE00B42XCP33.USD","LU0861579265.USD","LU0943347566.SGD","LU1244550577.SGD","LU0689626769.HKD","IE00BLSP4239.USD","LU0058720904.USD","LU0310799852.SGD","LU0868494617.USD","LU0289739343.SGD","LU1934455194.USD","BK4534","IE00BVYPNV92.GBP","LU0432979614.USD","LU0545039389.USD","IE000WAW04H5.SGD","LU1023059063.AUD","LU0128525929.USD","LU2237443465.HKD","LU2237443978.SGD","LU0234572021.USD","LU0472753341.HKD","LU1037948897.HKD","LU0198837287.USD","LU1003077747.HKD","LU1989772923.USD","IE00BJT1NW94.SGD","LU1162221912.USD","LU0203345920.USD","IE00BN8TJ469.HKD","LU1291159041.SGD","LU1839511570.USD","IE0000B7K699.USD","LU1057294990.SGD","LU0965508806.USD","LU0289961442.SGD","LU0310800379.SGD","LU0158827948.USD","LU0511384066.AUD","LU0965509283.SGD","LU2089283258.USD","LU1074936037.SGD","LU2129689514.USD","IE00BSNM7G36.USD","LU2237443895.HKD","LU1244550221.USD","SG9999015945.SGD","LU1093756168.USD","LU0211327993.USD","IE00BJJMRZ35.SGD","LU1496350171.SGD","IE0004445239.USD","LU2237443622.USD","LU0795875169.SGD","LU0795875086.SGD","LU0211328371.USD","LU1585245621.USD","LU2347655156.SGD","LU0057025933.USD","LU0170899867.USD","LU1244550494.USD","LU0942090050.USD","IE00B2B36J28.USD","LU2468319806.SGD","BK4566","BK4139","LU2112291526.USD","IE00BVYPNW00.USD","BK4585","IE000MB6IJN5.SGD","LU0122379950.USD","LU2129689605.HKD","IE0002141913.USD","BK4533","LU0882574055.USD","LU1061106388.HKD","LU1551013425.SGD","LU1989771016.USD","IE00B19Z3581.USD","LU2089284900.SGD","IE00B4R5TH58.HKD","LU0256863902.USD","LU0114720955.EUR","LU0256863811.USD","LU1430594728.SGD","IE000BZT7R73.USD","LU0289739699.SGD","LU0912757837.SGD","BK4581","LU2357627491.SGD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU1267930490.SGD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638687536","title":"艾伯维(ABBV.US)CD123 ADC获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2638687536","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638687536?lang=zh_cn&edition=full","pubTime":"2026-05-28 15:36","pubTimestamp":1779953784,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维宣布美国FDA已经批准其ADC疗法Pivekimab sunirine上市，用于治疗母细胞性浆细胞样树突细胞肿瘤。资料显示，这是全球首个获批上市的CD123 ADC，也是艾伯维首个获批的血液瘤ADC。Pivekimab sunirine是一款靶向CD123的ADC，拟开发用于治疗血液系统恶性肿瘤。CD123靶点在BPDCN肿瘤细胞中呈高度特异性高表达，是该病理想的治疗靶点。美国FDA已于2020年10月授予该药物BPDCN适应症突破性疗法认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999015986.USD","LU0211327993.USD","LU1244550494.USD","IE0000B7K699.USD","LU1267930573.SGD","SG9999003800.SGD","SG9999015978.USD","BK4533","BK4559","LU0289739343.SGD","LU0114720955.EUR","LU0472753341.HKD","LU0795875169.SGD","IE000BZT7R73.USD","IE00BBT3K403.USD","LU2357627491.SGD","BK4566","LU0289961442.SGD","LU0965509101.SGD","IPOS","LU2089984988.USD","SG9999011175.SGD","LU0661504455.SGD","ABBV","LU1732799900.SGD","LU1934455277.USD","LU0198837287.USD","LU1989771016.USD","LU1718418525.SGD","LU2089284900.SGD","IE0002270589.USD","LU1023059063.AUD","ADC","IE00BLSP4239.USD","LU0820561909.HKD","LU1037948897.HKD","LU0158827948.USD","LU0029864427.USD","LU2237443465.HKD","LU2237443895.HKD","BK4581","IE00B42XCP33.USD","BK4080","LU1061106388.HKD","LU0965509283.SGD","LU1267930490.SGD","LU0965509010.AUD","LU2133065610.SGD","LU1839511570.USD","IE00BVYPNV92.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199694110","title":"FDA：Pivekimab Sunirine-Pvzy处方信息新增黑框警告，提示肝毒性风险，包括肝窦阻塞综合征","url":"https://stock-news.laohu8.com/highlight/detail?id=1199694110","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199694110?lang=zh_cn&edition=full","pubTime":"2026-05-28 03:30","pubTimestamp":1779910214,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）宣布，已更新Pivekimab Sunirine-Pvzy的处方信息，要求其加入关于肝毒性的黑框警告，其中特别指出了肝窦阻塞综合征（曾称为肝静脉闭塞性疾病）的风险。这一强制性警告旨在提醒医疗专业人员和患者，使用该药物可能引发严重甚至致命的肝脏损伤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1983299246.USD","LU1291159041.SGD","LU1023059063.AUD","BK4550","LU2237443978.SGD","IE00BGHQF631.EUR","LU2129689605.HKD","BK4534","SG9999003800.SGD","IE00B19Z3B42.SGD","LU0128525929.USD","LU1839511570.USD","LU1003077747.HKD","LU0098860793.USD","LU1074936037.SGD","IE00BLSP4452.SGD","LU0689472784.USD","BK4533","LU2357627491.SGD","SG9999015986.USD","BK4581","LU0256863811.USD","LU2133065610.SGD","LU0868494617.USD","LU0882574055.USD","LU0912757837.SGD","LU0823416689.USD","LU0553294199.USD","LU0069063385.USD","LU2023251221.USD","IE0002141913.USD","LU0170899867.USD","LU2237443622.USD","IE00BJT1NW94.SGD","LU1732800096.USD","LU1989772840.SGD","LU1244550221.USD","LU1244550577.SGD","IE00BN8TJ469.HKD","LU0545039389.USD","LU0868494708.USD","LU1934455194.USD","SG9999015978.USD","LU0057025933.USD","LU0320765646.SGD","LU1244550494.USD","LU0289739343.SGD","IE000WAW04H5.SGD","LU0456855351.SGD","LU0122379950.USD","LU0058720904.USD","BK4559","LU0820561909.HKD","LU2237443382.USD","LU0949170772.SGD","LU1267930573.SGD","LU2089984988.USD","SG9999011175.SGD","SG9999015945.SGD","LU1496350171.SGD","LU2347655156.SGD","BK4585","LU0289961442.SGD","LU0211328371.USD","LU1585245621.USD","LU2237443549.SGD","LU0234572021.USD","LU2129689514.USD","BK4139","LU1718418525.SGD","LU0985320562.USD","LU0965509101.SGD","IE0009355771.USD","LU1551013425.SGD","LU0124676726.USD","LU1732799900.SGD","LU0029864427.USD","LU0738911758.USD","IE00B19Z3581.USD","LU1430594728.SGD","LU1496350502.SGD","LU0203347892.USD","LU0114720955.EUR","IE000SO60NU8.SGD","IE000BZT7R73.USD","IE00BLSP4239.USD","LU1093756325.SGD","IE00B4R5TH58.HKD","LU1267930490.SGD","LU0511384066.AUD","IE00BVYPNV92.GBP","LU0965509283.SGD","IE0004445239.USD","LU0203345920.USD","LU0432979614.USD","LU0820561818.USD","IE0000B7K699.USD","IE00BBT3K403.USD","LU0234570918.USD","LU0310800379.SGD","LU1037948897.HKD","LU1989771016.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU2089284900.SGD","IE000MB6IJN5.SGD","LU0158827948.USD","LU2129689431.USD","LU0859254822.USD","LU0472753341.HKD","IE00BSNM7G36.USD","LU0965508806.USD","LU1551013342.USD","LU0689626769.HKD","LU2237443465.HKD","IE00B2B36J28.USD","LU0661504455.SGD","LU0795875086.SGD","IE0002270589.USD","SG9999001440.SGD","LU0198837287.USD","LU1929549753.HKD","LU2468319806.SGD","LU1037948541.HKD","LU2112291526.USD","LU2237443895.HKD","LU0708994859.HKD","BK4588","IE00BDGV0183.EUR","ABBV","IE00BJJMRZ35.SGD","BK4566","LU1989772923.USD","IE000F7OJYX1.SGD","LU2089283258.USD","LU2087621335.USD","LU1057294990.SGD","SG9999015952.SGD","LU0861579265.USD","LU0942090050.USD","IE00B42XCP33.USD","LU1162221912.USD","LU0289739699.SGD","LU1934455277.USD","LU0965509010.AUD","IE00B3PB1722.GBP","LU0211327993.USD","LU0256863902.USD","LU1934455863.HKD","LU1093756168.USD","IE00BVYPNW00.USD","LU0310799852.SGD","LU0417517546.SGD","LU0943347566.SGD","LU0795875169.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159842356","title":"FDA批准Pivekimab Sunirine-Pvzy用于治疗超罕见血液恶性肿瘤——母细胞性浆细胞样树突状细胞肿瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1159842356","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159842356?lang=zh_cn&edition=full","pubTime":"2026-05-28 03:27","pubTimestamp":1779910079,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准Pivekimab Sunirine-Pvzy，用于治疗一种极为罕见的血液系统恶性肿瘤——母细胞性浆细胞样树突状细胞肿瘤。\n这一决定为患有这种侵袭性疾病的患者带来了新的治疗选择。BPDCN是一种罕见且通常难以治疗的癌症，主要影响皮肤、骨髓和血液。Pivekimab Sunirine-Pvzy的获批标志着该疾病治疗领域的一个重要里程碑。\n该药物的批准基于其在一系列临床研究中展现出的疗效与安全性数据，满足了当前未被满足的医疗需求。对于受此疾病困扰的患者及其家庭而言，此次获批无疑是一则积极消息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","IE00BVYPNW00.USD","LU1989772840.SGD","LU2129689514.USD","SG9999003800.SGD","IE00B4R5TH58.HKD","LU1496350171.SGD","LU0965509101.SGD","ABBV","SG9999015945.SGD","SG9999015986.USD","IE00BLSP4452.SGD","LU2237443895.HKD","BK4559","LU0057025933.USD","LU2023251221.USD","BK4534","IE0009355771.USD","LU0029864427.USD","LU0965509283.SGD","IE0002141913.USD","IE00BN8TJ469.HKD","LU0868494708.USD","BK4585","LU1267930573.SGD","LU1003077747.HKD","BK4139","LU0823416689.USD","LU1074936037.SGD","LU0310800379.SGD","LU1989771016.USD","LU0203345920.USD","LU1093756168.USD","LU0545039389.USD","LU2237443978.SGD","IE00BFTCPJ56.SGD","LU0069063385.USD","IE00BSNM7G36.USD","LU0861579265.USD","LU0114720955.EUR","IE0004445239.USD","LU0820561909.HKD","LU0820561818.USD","IE00B2B36J28.USD","LU0234570918.USD","LU1551013342.USD","BK4566","LU0859254822.USD","IE0000B7K699.USD","LU0122379950.USD","LU0965508806.USD","BK4581","LU1244550221.USD","LU1037948897.HKD","LU0211328371.USD","LU0289961442.SGD","IE00B42XCP33.USD","LU0661504455.SGD","LU1291159041.SGD","LU0098860793.USD","IE000WAW04H5.SGD","LU1162221912.USD","SG9999015978.USD","LU0124676726.USD","LU0320765646.SGD","LU1983299246.USD","IE000BZT7R73.USD","LU1718418525.SGD","IE00BLSP4239.USD","LU0949170772.SGD","LU1732800096.USD","LU0882574055.USD","IE00BGHQF631.EUR","LU2237443382.USD","SG9999001440.SGD","LU0256863902.USD","LU0912757837.SGD","LU2347655156.SGD","LU1934455194.USD","IE0002270589.USD","LU0128525929.USD","LU0738911758.USD","IE00B19Z3B42.SGD","LU2129689605.HKD","LU0310799852.SGD","LU0417517546.SGD","LU0256863811.USD","LU0689472784.USD","LU0985320562.USD","LU1267930490.SGD","LU2129689431.USD","LU1551013425.SGD","LU0456855351.SGD","LU0868494617.USD","LU1732799900.SGD","LU1244550577.SGD","LU2237443549.SGD","LU0511384066.AUD","LU0472753341.HKD","LU0211327993.USD","LU2468319806.SGD","LU1989772923.USD","LU1023059063.AUD","LU1496350502.SGD","LU0689626769.HKD","IE000MB6IJN5.SGD","BK4588","BK4533","IE00BVYPNV92.GBP","IE00B19Z3581.USD","IE00BBT3K403.USD","LU0553294199.USD","LU1839511570.USD","BK4550","LU2112291526.USD","LU0795875086.SGD","LU0965509010.AUD","LU2357627491.SGD","LU0158827948.USD","LU0942090050.USD","LU0943347566.SGD","LU0432979614.USD","LU2237443465.HKD","LU2089284900.SGD","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU1585245621.USD","LU2087621335.USD","LU1037948541.HKD","IE000SO60NU8.SGD","LU2089984988.USD","LU0198837287.USD","IE00BJT1NW94.SGD","SG9999011175.SGD","SG9999015952.SGD","LU0708994859.HKD","LU0289739699.SGD","LU0795875169.SGD","LU1093756325.SGD","IE00BDGV0183.EUR","LU0170899867.USD","IE00B3PB1722.GBP","LU1934455277.USD","LU0203347892.USD","LU0289739343.SGD","LU0234572021.USD","LU2133065610.SGD","LU1934455863.HKD","LU1244550494.USD","IE000F7OJYX1.SGD","LU1061106388.HKD","LU1430594728.SGD","LU2089283258.USD","LU1929549753.HKD","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138257792","title":"艾伯维宣布Maviret® (格卡瑞韦/哌仑他韦) 获CHMP积极意见 用于治疗急性丙型肝炎感染","url":"https://stock-news.laohu8.com/highlight/detail?id=1138257792","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138257792?lang=zh_cn&edition=full","pubTime":"2026-05-22 20:01","pubTimestamp":1779451282,"startTime":"0","endTime":"0","summary":"艾伯维公司近日宣布，其丙肝治疗药物Maviret®（格卡瑞韦/哌仑他韦组合）已获得欧洲药品管理局人用药品委员会（CHMP）的积极意见，该意见支持将该药物用于治疗急性丙型肝炎感染。这一进展为拓宽Maviret®的适用范围、惠及更多患者群体铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0738911758.USD","LU0432979614.USD","LU1934455277.USD","BK4533","IE00BN8TJ469.HKD","LU1989771016.USD","BK4585","LU0868494708.USD","LU0456855351.SGD","LU0689472784.USD","IE00BGHQF631.EUR","SG9999015978.USD","LU0823416689.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BVYPNV92.GBP","LU0553294199.USD","LU1718418525.SGD","BK4534","LU0320765646.SGD","IE000MB6IJN5.SGD","BK4581","LU2347655156.SGD","LU0820561909.HKD","LU0943347566.SGD","LU0949170772.SGD","IE00BLSP4452.SGD","LU0545039389.USD","IE0002141913.USD","LU1093756168.USD","LU2237443382.USD","BK4566","LU0795875169.SGD","LU0985320562.USD","LU2468319806.SGD","LU1037948897.HKD","IE000WAW04H5.SGD","SG9999011175.SGD","IE000SO60NU8.SGD","IE000BZT7R73.USD","LU0058720904.USD","IE0009355771.USD","LU1057294990.SGD","LU0098860793.USD","IE00B3PB1722.GBP","LU0310799852.SGD","LU1267930573.SGD","LU0861579265.USD","IE0000B7K699.USD","SG9999015945.SGD","LU0689626769.HKD","LU0203345920.USD","LU1267930490.SGD","LU0211327993.USD","LU0289739343.SGD","LU1244550221.USD","ABBV","BK4550","LU0198837287.USD","LU0859254822.USD","LU0965509283.SGD","IE00BFTCPJ56.SGD","BK4559","LU0472753341.HKD","LU2357627491.SGD","LU0069063385.USD","LU0310800379.SGD","LU2087621335.USD","LU1983299246.USD","LU2237443622.USD","LU0114720955.EUR","LU0417517546.SGD","LU1003077747.HKD","BK4139","IE0004445239.USD","IE00BVYPNW00.USD","LU1162221912.USD","SG9999003800.SGD","LU1551013342.USD","LU1061106388.HKD","LU0256863811.USD","LU2237443895.HKD","LU0057025933.USD","LU2089984988.USD","SG9999001440.SGD","LU2129689605.HKD","LU1023059063.AUD","LU1989772923.USD","IE00BSNM7G36.USD","LU1244550494.USD","LU2129689431.USD","LU0942090050.USD","IE00B19Z3581.USD","IE0002270589.USD","IE000F7OJYX1.SGD","LU0029864427.USD","LU0511384066.AUD","LU0203347892.USD","LU0912757837.SGD","LU2089283258.USD","BK4588","LU0256863902.USD","LU2023251221.USD","LU0234572021.USD","IE00BDGV0183.EUR","LU0234570918.USD","LU1037948541.HKD","LU1585245621.USD","LU2112291526.USD","LU0128525929.USD","LU1934455863.HKD","LU2089284900.SGD","IE00B42XCP33.USD","LU0170899867.USD","LU1732800096.USD","LU1839511570.USD","LU1934455194.USD","LU2237443465.HKD","LU0122379950.USD","LU0289961442.SGD","IE00BJJMRZ35.SGD","LU0708994859.HKD","LU1929549753.HKD","LU1074936037.SGD","LU0158827948.USD","LU2237443978.SGD","LU1093756325.SGD","LU1989772840.SGD","LU0211328371.USD","LU1244550577.SGD","LU0882574055.USD","IE00BBT3K403.USD","SG9999015986.USD","LU0124676726.USD","IE00B19Z3B42.SGD","LU1496350171.SGD","LU1732799900.SGD","LU0965508806.USD","LU0661504455.SGD","LU1430594728.SGD","LU0965509010.AUD","LU2129689514.USD","LU0795875086.SGD","IE00B2B36J28.USD","LU2237443549.SGD","LU0868494617.USD","IE00BLSP4239.USD","LU1551013425.SGD","LU0820561818.USD","LU1496350502.SGD","SG9999015952.SGD","LU0965509101.SGD","LU2133065610.SGD","LU1291159041.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141853478","title":"艾伯维旗下爱力根美学获CHMP积极意见：Boey®有望改善成人中重度眉间纹","url":"https://stock-news.laohu8.com/highlight/detail?id=1141853478","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141853478?lang=zh_cn&edition=full","pubTime":"2026-05-22 04:11","pubTimestamp":1779394284,"startTime":"0","endTime":"0","summary":"这一积极意见是Boey在欧盟市场获批上市前的关键步骤。若最终获得批准，该产品将为寻求改善眉间纹外观的成年人提供一种新的治疗选择。爱力根美学在神经调节剂领域拥有深厚的研发经验，此次进展进一步巩固了其在医学美学领域的创新地位。眉间纹是面部常见的动态皱纹，由反复的肌肉收缩形成。公司表示，将继续与监管机构合作，推动该产品后续的审批进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","LU0553294199.USD","LU1983299246.USD","LU0289739699.SGD","LU0289961442.SGD","IE000SO60NU8.SGD","LU0256863811.USD","LU1162221912.USD","LU0965509283.SGD","LU1496350171.SGD","LU0310800379.SGD","LU1989772923.USD","IE0002141913.USD","LU1037948897.HKD","LU2237443549.SGD","IE00BGHQF631.EUR","LU0823416689.USD","LU0114720955.EUR","IE00BJT1NW94.SGD","LU1718418525.SGD","LU0170899867.USD","LU1037948541.HKD","SG9999015986.USD","LU0820561818.USD","LU0122379950.USD","LU0942090050.USD","LU2129689514.USD","SG9999015945.SGD","LU0965509101.SGD","LU0058720904.USD","IE00BFTCPJ56.SGD","LU0211327993.USD","LU0198837287.USD","IE00BJJMRZ35.SGD","LU1551013342.USD","LU2089984988.USD","LU0795875086.SGD","LU1934455863.HKD","LU2237443978.SGD","LU2357627491.SGD","LU0795875169.SGD","LU0868494708.USD","LU0234570918.USD","LU1496350502.SGD","SG9999003800.SGD","LU0859254822.USD","LU0289739343.SGD","LU1989772840.SGD","LU2237443622.USD","LU1023059063.AUD","LU0417517546.SGD","LU1585245621.USD","BK4534","LU0965509010.AUD","LU0456855351.SGD","IE000WAW04H5.SGD","LU0472753341.HKD","IE0000B7K699.USD","LU0545039389.USD","LU1003077747.HKD","LU2129689605.HKD","IE000F7OJYX1.SGD","LU0128525929.USD","IE000MB6IJN5.SGD","BK4550","LU0057025933.USD","LU0912757837.SGD","LU1061106388.HKD","BK4533","LU0234572021.USD","LU1989771016.USD","LU2468319806.SGD","LU1244550221.USD","LU2237443465.HKD","SG9999015978.USD","LU0949170772.SGD","LU0124676726.USD","LU2237443895.HKD","LU1244550494.USD","IE00BBT3K403.USD","IE00B19Z3581.USD","IE00BVYPNV92.GBP","LU0965508806.USD","LU2089283258.USD","LU0256863902.USD","BK4581","IE00BLSP4452.SGD","LU2023251221.USD","LU0661504455.SGD","LU0689472784.USD","IE00BLSP4239.USD","LU2089284900.SGD","LU0069063385.USD","IE00B3PB1722.GBP","LU0943347566.SGD","LU0203347892.USD","IE000BZT7R73.USD","LU1551013425.SGD","IE0009355771.USD","LU1267930490.SGD","IE00BN8TJ469.HKD","ABBV","LU1093756168.USD","LU1732799900.SGD","IE00B2B36J28.USD","LU0689626769.HKD","LU0861579265.USD","LU0203345920.USD","LU1057294990.SGD","IE00B4R5TH58.HKD","LU0708994859.HKD","LU1839511570.USD","LU1732800096.USD","IE00BVYPNW00.USD","LU1430594728.SGD","BK4585","LU0310799852.SGD","LU0738911758.USD","LU2087621335.USD","LU1074936037.SGD","IE00B42XCP33.USD","LU0985320562.USD","LU2129689431.USD","IE00BSNM7G36.USD","LU2133065610.SGD","BK4559","LU1934455194.USD","LU1934455277.USD","LU0882574055.USD","SG9999015952.SGD","LU0098860793.USD","LU0511384066.AUD","LU1267930573.SGD","SG9999011175.SGD","BK4139","LU1929549753.HKD","LU0211328371.USD","LU1244550577.SGD","IE0004445239.USD","LU2112291526.USD","IE00BDGV0183.EUR","LU1291159041.SGD","LU0868494617.USD","BK4588","LU2347655156.SGD","LU1093756325.SGD","IE0002270589.USD","LU2237443382.USD","LU0029864427.USD","LU0432979614.USD","LU0820561909.HKD","LU0158827948.USD","SG9999001440.SGD","IE00B19Z3B42.SGD","LU0320765646.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138036084","title":"阿布扎比主权基金大幅减持西维斯健康股份，持股量骤降逾六成","url":"https://stock-news.laohu8.com/highlight/detail?id=1138036084","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138036084?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:30","pubTimestamp":1778855441,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件披露，阿布扎比主权财富基金穆巴达拉投资公司已大幅削减了其在西维斯健康的持股。此次减持幅度高达63.4%，使其持有的股份数量降至54,800股。\n这一变动标志着该主权基金对这家美国医疗保健巨头投资策略的显著调整。文件显示，经过此次操作，穆巴达拉投资公司对西维斯健康的持股比例已大幅降低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0719512351.SGD","LU2023250843.SGD","LU2433249047.HKD","LU0310800379.SGD","LU1974910355.USD","LU1699723380.USD","LU2357305700.SGD","LU1992135399.USD","SG9999015952.SGD","IE00B7SZLL34.SGD","LU0056508442.USD","LU1718418525.SGD","LU0208291251.USD","LU2089283258.USD","LU0511384066.AUD","LU0957791311.USD","LU0069063385.USD","LU1732799900.SGD","LU1732800096.USD","IE00B4R5TH58.HKD","LU0029864427.USD","LU0545039389.USD","LU0048584097.USD","LU1670627923.USD","LU0082616367.USD","LU0122379950.USD","LU1037948541.HKD","LU2237443549.SGD","LU0823416689.USD","LU1989772923.USD","LU2089984988.USD","BK4534","SG9999011175.SGD","IE00BSNM7G36.USD","IE0005OL40V9.USD","IE000WAW04H5.SGD","LU2112291526.USD","LU0124676726.USD","LU1235294995.USD","IE00BDGV0183.EUR","IE00B42XCP33.USD","LU0456855351.SGD","LU1037948897.HKD","LU2468319806.SGD","LU0868494617.USD","IE00B2B36J28.USD","LU1244550494.USD","LU1585245621.USD","LU1061106388.HKD","BK4566","LU0203345920.USD","LU1815333072.USD","BK4551","LU0096362180.USD","LU0098860793.USD","LU0823434740.USD","LU0820561818.USD","LU1059921491.USD","LU1023059063.AUD","LU0289739699.SGD","LU1852331112.SGD","LU1720051017.SGD","IE00BN29S564.USD","BK4585","LU0058720904.USD","LU0985320562.USD","IE00BZ1G4Q59.USD","LU1934455863.HKD","IE00BQXX3D17.EUR","SG9999015978.USD","BK4559","IE00BJJMRY28.SGD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU1934455194.USD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","LU0061474960.USD","LU0708994859.HKD","LU0417517546.SGD","LU1571399168.USD","LU0882574055.USD","LU2322448791.USD","IE00BKVL7J92.USD","LU0738911758.USD","IE00BBT3K403.USD","IE00BFSS8Q28.SGD","LU1983299246.USD","LU1496350171.SGD","LU2023251221.USD","LU2133065610.SGD","IE00BFSS7M15.SGD","LU0320765489.SGD","LU0348723411.USD","LU0957808578.USD","LU1074936037.SGD","LU2129689605.HKD","LU2237443382.USD","LU0198837287.USD","LU0942090050.USD","LU1551013342.USD","LU1823568750.SGD","LU0157215616.USD","LU2242649171.HKD","IE00BVYPNV92.GBP","IE00BLSP4239.USD","SG9999003800.SGD","LU1720051108.HKD","LU0211331839.USD","LU2244417387.USD","IE00BVYPNW00.USD","LU2357627491.SGD","IE0002141913.USD","LU0444973449.USD","LU2087621335.USD","LU0006061336.USD","LU2272731865.HKD","LU1267930573.SGD","LU2360106780.USD","LU0661504455.SGD","LU1917777945.USD","LU2089985449.USD","LU2023250504.SGD","LU0072461881.USD","CVS","SG9999001440.SGD","LU2931357623.SGD","LU1057294990.SGD","LU0868494708.USD","LU1366333091.USD","LU2237443465.HKD","LU1244550577.SGD","LU2129689431.USD","LU0861579265.USD","BK4581","LU0859254822.USD","LU2089284900.SGD","LU0965509101.SGD","LU1093756168.USD","LRCX","BK4588","IE00BFTCPJ56.SGD","LU0476273544.USD","IE000MB6IJN5.SGD","LU0070302665.USD","LU0256863811.USD","LU2125909247.SGD","LU0472753341.HKD","LU1992135472.HKD","LU0158827948.USD","LU0211328371.USD","LU1642822529.SGD","LU0820561909.HKD","LU1548497426.USD","IE000BZT7R73.USD","IE00B1BXHZ80.USD","LU2106854487.HKD","LU0170899867.USD","LU1430594728.SGD","LU0274383776.USD","LU0234570918.USD","LU0203347892.USD","IE00BGHQF631.EUR","LU1035773651.USD","LU2272731782.SGD","LU0114720955.EUR","BK4147","IE00BJJMRX11.SGD","LU0965508806.USD","LU1244550221.USD","SG9999015986.USD","BK4550","BK4543","LU0795875086.SGD","LU2322448957.HKD","LU0057025933.USD","BK4504","LU2129689514.USD","LU2237443978.SGD","LU1989772840.SGD","IE00B3PB1722.GBP","IE00B7KXQ091.USD","IE0004445015.USD","LU1923622614.USD","LU2125909593.SGD","IE0000B7K699.USD","IE00B5949003.HKD","LU0128525929.USD","LU2237443622.USD","LRCU","LU1046421795.USD","LU0444971666.USD","IE00BJT1NW94.SGD","LU1839511570.USD","LU1496350502.SGD","IE0004445239.USD","LU0251132253.USD","LU0289739343.SGD","LU0320765646.SGD","LU0553294199.USD","IE0002270589.USD","LU0949170772.SGD","ABBV","IE00BN8TJ469.HKD","LU0289961442.SGD","LU0912757837.SGD","IE000F7OJYX1.SGD","LU0061475181.USD","LU0965509010.AUD","BK4533","IE00BLSP4452.SGD","LU0965509283.SGD","LU1670628061.USD","LU0689626769.HKD","LU1291159041.SGD","LU0187121727.USD","LU0310799852.SGD","LU1003077747.HKD","LU1162221912.USD","LU2272731600.USD","LU1267930490.SGD","BK4196","IE000SO60NU8.SGD","IE00B775H168.HKD","LU0162691827.USD","SG9999015945.SGD","LU0943347566.SGD","BK4139","LU1069347547.HKD","LU1551013425.SGD","LU1815336760.USD","LU0097036916.USD","LU2237443895.HKD","LU2250418816.HKD","LU1934455277.USD","LU0689472784.USD","LU1929549753.HKD","LU0432979614.USD","LU0211327993.USD","LU0234572021.USD","IE0009355771.USD","LU2473716301.USD","LU0081259029.USD","LU1989771016.USD","BK4567","IE00B19Z3581.USD","LU0823434583.USD","IE00B19Z3B42.SGD","IE0009356076.USD","LU0256863902.USD","IE00B4JS1V06.HKD","LU0795875169.SGD","LU2347655156.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197085447","title":"今年投资者纷纷涌入高股息股，这些标的位列华尔街买入名单","url":"https://stock-news.laohu8.com/highlight/detail?id=1197085447","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197085447?lang=zh_cn&edition=full","pubTime":"2026-05-12 14:29","pubTimestamp":1778567343,"startTime":"0","endTime":"0","summary":"今年以来，投资者纷纷涌入高股息股票，以规避市场波动。晨星数据显示，2026年第一季度有近220亿美元流入股息型交易所交易基金，为2022年第二季度以来的最高单季流入额。同时，这些股票的股息率均高于1.5%，超过标普500当前1.03%的股息率。这家生物制药公司股价今年迄今已下跌约11%。PPL 股息率为3.1%，相较于平均目标价有17%的上行空间，约67%的分析师给予“买入”评级。","market":"us","thumbnail":"https://community-static.tradeup.com/news/df8ebdaecb9fa2ea4202cc72251a445c","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/df8ebdaecb9fa2ea4202cc72251a445c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"9409577ccefb8f7fb8858c7755e41b56","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPL","CVX","ABBV","PNC"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2631560116","title":"艾伯维(ABBV.US)乌帕替尼斑秃适应症已向美国FDA递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2631560116","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631560116?lang=zh_cn&edition=full","pubTime":"2026-04-29 16:40","pubTimestamp":1777452029,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月28日，艾伯维宣布，已向美国FDA递交乌帕替尼的新适应症上市申请，用于治疗成人和12岁及以上青少年重度斑秃。乌帕替尼是艾伯维研发的一款口服、高选择性JAK1抑制剂，目前正在多种免疫介导性疾病中对其进行研究。乌帕替尼于2019年首次在美国获批上市，2022年2月获批进入中国。艾伯维表示，乌帕替尼正在针对斑秃、化脓性汗腺炎、大动脉炎、系统性红斑狼疮及白癜风开展III期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0256863902.USD","LU2023251221.USD","LU0211327993.USD","IE00BVYPNW00.USD","SG9999001440.SGD","IE00B42XCP33.USD","SG9999003800.SGD","LU1244550221.USD","LU2468319806.SGD","LU0511384066.AUD","IE0009355771.USD","LU1496350502.SGD","SG9999015952.SGD","LU0289961442.SGD","LU0949170772.SGD","LU0820561909.HKD","IE00BJJMRZ35.SGD","LU0069063385.USD","LABU","LU1074936037.SGD","LU2089284900.SGD","LU0432979614.USD","LU2112291526.USD","LU1003077747.HKD","LU0256863811.USD","IE00BSNM7G36.USD","LU0310800379.SGD","LU1267930573.SGD","IE000MB6IJN5.SGD","LU0795875169.SGD","LU0823416689.USD","LU0029864427.USD","IE0004445239.USD","LU2237443465.HKD","IE000BZT7R73.USD","IPOS","LU2357627491.SGD","LU0689472784.USD","LU0289739699.SGD","ABBV","LU1244550577.SGD","BK4139","LU1291159041.SGD","LU2129689431.USD","IE000SO60NU8.SGD","BK4581","LU1267930490.SGD","LU0211328371.USD","LU0128525929.USD","LU0965509101.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103715471","title":"艾伯维向FDA提交乌帕替尼治疗重度斑秃成人与青少年患者的新适应症申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1103715471","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103715471?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:03","pubTimestamp":1777377803,"startTime":"0","endTime":"0","summary":"艾伯维公司已正式向美国食品药品监督管理局提交乌帕替尼（商品名：Rinvoq®）的新适应症申请，寻求批准该药物用于治疗成人和青少年重度斑秃患者。\n此次申报标志着JAK抑制剂在自身免疫性皮肤病治疗领域的重要拓展。若获批准，乌帕替尼将成为该疾病领域首个适用于青少年群体的靶向治疗选择，为深受斑秃困扰的患者提供新的治疗希望。\n临床研究数据显示，乌帕替尼在促进毛发再生方面展现出显著疗效。其作用机制通过选择性抑制JAK通路，有效阻断导致毛囊炎症的关键细胞因子信号传导。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0511384066.AUD","LU2129689514.USD","LU0211327993.USD","LU0545039389.USD","LU2112291526.USD","SG9999003800.SGD","LU1585245621.USD","LU0234572021.USD","LU1162221912.USD","IE0004445239.USD","LU0114720955.EUR","LU1934455863.HKD","LU0868494708.USD","IE00BBT3K403.USD","LU0456855351.SGD","BK4566","IE00B19Z3B42.SGD","LU0942090050.USD","LU0417517546.SGD","BK4550","LU2023251221.USD","LU0289739699.SGD","IE000SO60NU8.SGD","LU0234570918.USD","LU0432979614.USD","LU0820561909.HKD","LU0058720904.USD","BK4585","LU0158827948.USD","LU1291159041.SGD","IE00BLSP4452.SGD","IE00B42XCP33.USD","LU0965509283.SGD","LU1496350502.SGD","LU0965509010.AUD","LU0122379950.USD","LU1989772840.SGD","LU1496350171.SGD","LU2237443549.SGD","BK4588","LU1551013342.USD","LU2129689605.HKD","SG9999015986.USD","LU2237443622.USD","IE00BSNM7G36.USD","LU0203345920.USD","LU0069063385.USD","IE00B2B36J28.USD","SG9999001440.SGD","SG9999015978.USD","LU0949170772.SGD","LU2237443978.SGD","IE00BGHQF631.EUR","LU2347655156.SGD","LU0289739343.SGD","LU0472753341.HKD","LU2357627491.SGD","LU0256863902.USD","LU0124676726.USD","SG9999011175.SGD","LU1929549753.HKD","ABBV","LU1732799900.SGD","IE00B4R5TH58.HKD","LU0868494617.USD","IE00BFTCPJ56.SGD","LU2089284900.SGD","BK4139","IE0002270589.USD","LU1023059063.AUD","LU1037948897.HKD","LU0708994859.HKD","LU0211328371.USD","LU1989772923.USD","SG9999015952.SGD","IE000MB6IJN5.SGD","IE00BDGV0183.EUR","LU0689472784.USD","LU1430594728.SGD","LU1732800096.USD","LU1839511570.USD","BK4534","LU0738911758.USD","LU1057294990.SGD","LU0553294199.USD","IE0000B7K699.USD","IE00BJJMRZ35.SGD","LU1244550221.USD","LU0689626769.HKD","IE00BVYPNW00.USD","IE000F7OJYX1.SGD","LU0882574055.USD","LU0795875169.SGD","IE000BZT7R73.USD","LU1003077747.HKD","LU0965509101.SGD","LU2087621335.USD","LU2089984988.USD","LU0820561818.USD","LU0661504455.SGD","LU2237443382.USD","IE00BJT1NW94.SGD","LU0795875086.SGD","LU0861579265.USD","LU1718418525.SGD","LU1037948541.HKD","LU0985320562.USD","LU0098860793.USD","IE00BLSP4239.USD","LU0057025933.USD","IE0002141913.USD","LU2237443465.HKD","LU0029864427.USD","LU1244550577.SGD","LU0256863811.USD","LU0203347892.USD","LU0310799852.SGD","LU1061106388.HKD","LU1267930490.SGD","LU1983299246.USD","LU2468319806.SGD","LU1244550494.USD","LU1267930573.SGD","IE00BN8TJ469.HKD","BK4533","LU2089283258.USD","LU0912757837.SGD","LU1934455194.USD","BK4559","IE00B3PB1722.GBP","LU0823416689.USD","LU1074936037.SGD","LU1551013425.SGD","LU0128525929.USD","LU0170899867.USD","LU0289961442.SGD","IE0009355771.USD","LU2129689431.USD","LU1093756325.SGD","LU1934455277.USD","LU0198837287.USD","LU1989771016.USD","IE000WAW04H5.SGD","LU1093756168.USD","LU0859254822.USD","LU2237443895.HKD","BK4581","LU0965508806.USD","IE00B19Z3581.USD","LU0310800379.SGD","LU2133065610.SGD","SG9999015945.SGD","LU0943347566.SGD","IE00BVYPNV92.GBP","LU0320765646.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148221705","title":"艾伯维Rinvoq在12周疗效评估中展现优于Humira的低疾病活动度和缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=1148221705","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148221705?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:06","pubTimestamp":1777374363,"startTime":"0","endTime":"0","summary":"艾伯维公司旗下药物Rinvoq在治疗类风湿关节炎的12周关键节点评估中，其诱导低疾病活动度及临床缓解的效果显著优于对照药物Humira。临床数据显示，接受Rinvoq治疗的患者组在疾病活动指数评分、关节肿胀压痛计数等核心指标上均取得更具统计学意义的改善。这一结果进一步巩固了Rinvoq作为中重度活动性类风湿关节炎患者重要治疗选择的临床地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1037948541.HKD","LU0943347566.SGD","BK4581","IE00BGHQF631.EUR","LU2237443465.HKD","LU0965509010.AUD","LU0965509101.SGD","LU0057025933.USD","LU0029864427.USD","LU1929549753.HKD","SG9999015986.USD","IE00BDGV0183.EUR","IE00BVYPNV92.GBP","LU0310800379.SGD","IE0002270589.USD","LU1551013425.SGD","LU2133065610.SGD","IE00BLSP4452.SGD","LU1496350171.SGD","SG9999015945.SGD","LU2347655156.SGD","LU2089284900.SGD","LU2089283258.USD","SG9999015952.SGD","LU1732799900.SGD","LU1839511570.USD","LU0456855351.SGD","IE0000B7K699.USD","LU0708994859.HKD","LU1989772923.USD","LU2129689514.USD","LU0820561818.USD","IE00B19Z3B42.SGD","LU0511384066.AUD","LU1718418525.SGD","LU0058720904.USD","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU0472753341.HKD","LU0417517546.SGD","IE000MB6IJN5.SGD","LU1244550577.SGD","LU0553294199.USD","LU2237443549.SGD","LU1732800096.USD","LU0234572021.USD","BK4139","LU0949170772.SGD","LU0868494708.USD","ABBV","LU1585245621.USD","LU0661504455.SGD","SG9999015978.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU0098860793.USD","LU0985320562.USD","IE00BBT3K403.USD","LU1244550221.USD","LU2089984988.USD","LU0942090050.USD","LU2112291526.USD","SG9999011175.SGD","LU0859254822.USD","IE000F7OJYX1.SGD","IE0009355771.USD","LU0203347892.USD","BK4559","IE000BZT7R73.USD","LU1983299246.USD","BK4550","LU1023059063.AUD","IE000SO60NU8.SGD","LU2087621335.USD","LU0912757837.SGD","LU0158827948.USD","LU0256863811.USD","IE00BSNM7G36.USD","SG9999001440.SGD","LU0545039389.USD","LU1934455863.HKD","LU0289739343.SGD","LU1989772840.SGD","LU0256863902.USD","LU2237443895.HKD","LU0320765646.SGD","LU2129689431.USD","LU0289739699.SGD","LU2023251221.USD","IE00BN8TJ469.HKD","LU0128525929.USD","LU0432979614.USD","IE00B19Z3581.USD","IE00BVYPNW00.USD","LU1989771016.USD","LU0211328371.USD","LU0310799852.SGD","LU0114720955.EUR","IE00B2B36J28.USD","LU0861579265.USD","LU0689472784.USD","LU0289961442.SGD","LU0965509283.SGD","BK4533","LU0965508806.USD","LU0795875169.SGD","LU1267930490.SGD","BK4585","LU1003077747.HKD","IE0004445239.USD","LU1061106388.HKD","BK4588","LU0689626769.HKD","LU0738911758.USD","LU1074936037.SGD","LU0198837287.USD","LU1093756325.SGD","LU1934455194.USD","BK4534","LU0203345920.USD","IE00BFTCPJ56.SGD","LU1244550494.USD","SG9999003800.SGD","LU1267930573.SGD","LU0122379950.USD","IE00BLSP4239.USD","LU1037948897.HKD","LU1551013342.USD","IE000WAW04H5.SGD","LU0069063385.USD","LU2357627491.SGD","LU1496350502.SGD","BK4566","LU0868494617.USD","LU2129689605.HKD","LU0820561909.HKD","LU1430594728.SGD","LU0823416689.USD","LU0124676726.USD","LU1093756168.USD","LU0882574055.USD","LU0170899867.USD","IE0002141913.USD","LU1162221912.USD","LU2237443622.USD","LU0795875086.SGD","IE00B42XCP33.USD","LU2237443382.USD","LU1291159041.SGD","IE00B3PB1722.GBP","IE00B4R5TH58.HKD","LU0234570918.USD","LU0211327993.USD","LU1934455277.USD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140955338","title":"Evolveimmune Therapeutics达成临床前里程碑 触发艾伯维1800万美元付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1140955338","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140955338?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:02","pubTimestamp":1777374151,"startTime":"0","endTime":"0","summary":"生物技术公司Evolveimmune Therapeutics近日宣布，其研发项目成功达到关键临床前里程碑。这一重要进展触发了与艾伯维公司合作协议中的付款条款。\n根据双方既定协议，艾伯维将向Evolveimmune支付高达1800万美元的里程碑款项。该笔资金将用于支持后续研发工作的持续推进。\n此次里程碑的达成，标志着双方合作项目取得了实质性突破。这不仅验证了Evolveimmune技术平台的有效性，也为项目向临床阶段推进奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0511384066.AUD","LU2129689514.USD","LU0211327993.USD","LU0545039389.USD","LU2112291526.USD","SG9999003800.SGD","LU1585245621.USD","LU0234572021.USD","LU1162221912.USD","IE0004445239.USD","LU0114720955.EUR","LU1934455863.HKD","LU0868494708.USD","IE00BBT3K403.USD","LU0456855351.SGD","BK4566","IE00B19Z3B42.SGD","LU0942090050.USD","LU0417517546.SGD","BK4550","LU2023251221.USD","LU0289739699.SGD","IE000SO60NU8.SGD","LU0234570918.USD","LU0432979614.USD","LU0820561909.HKD","LU0058720904.USD","BK4585","LU0158827948.USD","LU1291159041.SGD","IE00BLSP4452.SGD","IE00B42XCP33.USD","LU0965509283.SGD","LU1496350502.SGD","LU0965509010.AUD","LU0122379950.USD","LU1989772840.SGD","LU1496350171.SGD","LU2237443549.SGD","BK4588","LU1551013342.USD","LU2129689605.HKD","SG9999015986.USD","LU2237443622.USD","IE00BSNM7G36.USD","LU0203345920.USD","LU0069063385.USD","IE00B2B36J28.USD","SG9999001440.SGD","SG9999015978.USD","LU0949170772.SGD","LU2237443978.SGD","IE00BGHQF631.EUR","LU2347655156.SGD","LU0289739343.SGD","LU0472753341.HKD","LU2357627491.SGD","LU0256863902.USD","LU0124676726.USD","SG9999011175.SGD","LU1929549753.HKD","ABBV","LU1732799900.SGD","IE00B4R5TH58.HKD","LU0868494617.USD","IE00BFTCPJ56.SGD","LU2089284900.SGD","BK4139","IE0002270589.USD","LU1023059063.AUD","LU1037948897.HKD","LU0708994859.HKD","LU0211328371.USD","LU1989772923.USD","SG9999015952.SGD","IE000MB6IJN5.SGD","IE00BDGV0183.EUR","LU0689472784.USD","LU1430594728.SGD","LU1732800096.USD","LU1839511570.USD","BK4534","LU0738911758.USD","LU1057294990.SGD","LU0553294199.USD","IE0000B7K699.USD","IE00BJJMRZ35.SGD","LU1244550221.USD","LU0689626769.HKD","IE00BVYPNW00.USD","IE000F7OJYX1.SGD","LU0882574055.USD","LU0795875169.SGD","IE000BZT7R73.USD","LU1003077747.HKD","LU0965509101.SGD","LU2087621335.USD","LU2089984988.USD","LU0820561818.USD","LU0661504455.SGD","LU2237443382.USD","IE00BJT1NW94.SGD","LU0795875086.SGD","LU0861579265.USD","LU1718418525.SGD","LU1037948541.HKD","LU0985320562.USD","LU0098860793.USD","IE00BLSP4239.USD","LU0057025933.USD","IE0002141913.USD","LU2237443465.HKD","LU0029864427.USD","LU1244550577.SGD","LU0256863811.USD","LU0203347892.USD","LU0310799852.SGD","LU1061106388.HKD","LU1267930490.SGD","LU1983299246.USD","LU2468319806.SGD","LU1244550494.USD","LU1267930573.SGD","IE00BN8TJ469.HKD","BK4533","LU2089283258.USD","LU0912757837.SGD","LU1934455194.USD","BK4559","IE00B3PB1722.GBP","LU0823416689.USD","LU1074936037.SGD","LU1551013425.SGD","LU0128525929.USD","LU0170899867.USD","LU0289961442.SGD","IE0009355771.USD","LU2129689431.USD","LU1093756325.SGD","LU1934455277.USD","LU0198837287.USD","LU1989771016.USD","IE000WAW04H5.SGD","LU1093756168.USD","LU0859254822.USD","LU2237443895.HKD","BK4581","LU0965508806.USD","IE00B19Z3581.USD","LU0310800379.SGD","LU2133065610.SGD","SG9999015945.SGD","LU0943347566.SGD","IE00BVYPNV92.GBP","LU0320765646.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144855855","title":"Evolveimmune Therapeutics与艾伯维合作达成临床前研究里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1144855855","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144855855?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:02","pubTimestamp":1777374151,"startTime":"0","endTime":"0","summary":"生物技术公司Evolveimmune Therapeutics宣布，其与全球生物制药巨头艾伯维公司的合作项目已成功实现关键临床前研究里程碑。这一进展标志着双方在创新疗法开发领域取得实质性突破，为后续临床研究奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","LU0417517546.SGD","LU1061106388.HKD","LU1934455277.USD","LU2357627491.SGD","LU0211328371.USD","SG9999011175.SGD","IE00B2B36J28.USD","SG9999015986.USD","IE00BVYPNV92.GBP","LU1162221912.USD","LU0511384066.AUD","LU0320765646.SGD","LU0882574055.USD","LU2347655156.SGD","LU0965508806.USD","LU0158827948.USD","LU0289961442.SGD","IE000SO60NU8.SGD","LU2089284900.SGD","LU0661504455.SGD","IE000WAW04H5.SGD","BK4550","BK4588","LU0820561818.USD","SG9999015978.USD","LU0128525929.USD","LU1037948897.HKD","IE000MB6IJN5.SGD","LU2112291526.USD","LU1989772840.SGD","IE0004445239.USD","LU1244550577.SGD","LU0868494617.USD","LU1244550494.USD","LU0289739343.SGD","LU0820561909.HKD","BK4139","LU0795875086.SGD","LU1244550221.USD","LU1267930490.SGD","LU1732799900.SGD","LU1551013342.USD","LU1585245621.USD","LU0432979614.USD","LU1989772923.USD","LU0823416689.USD","IE00B3PB1722.GBP","LU1496350502.SGD","LU0985320562.USD","LU0057025933.USD","IE00BDGV0183.EUR","SG9999001440.SGD","ABBV","LU1430594728.SGD","LU2237443978.SGD","LU1989771016.USD","LU1839511570.USD","LU0456855351.SGD","SG9999003800.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","LU0069063385.USD","LU0211327993.USD","LU0122379950.USD","LU0708994859.HKD","IE00B19Z3581.USD","LU1934455194.USD","LU1093756168.USD","LU0689626769.HKD","BK4534","BK4585","LU2089984988.USD","LU0310799852.SGD","BK4533","LU0289739699.SGD","LU0545039389.USD","LU0738911758.USD","LU1057294990.SGD","LU1074936037.SGD","LU1983299246.USD","LU0472753341.HKD","LU1003077747.HKD","LU0098860793.USD","LU2089283258.USD","IE00BJJMRZ35.SGD","IE00BVYPNW00.USD","IE0002141913.USD","LU1267930573.SGD","LU0965509010.AUD","LU1732800096.USD","LU2237443622.USD","IE00BLSP4452.SGD","LU0942090050.USD","LU0124676726.USD","LU1929549753.HKD","LU2237443465.HKD","LU0689472784.USD","LU1023059063.AUD","IE000F7OJYX1.SGD","LU1718418525.SGD","IE00BBT3K403.USD","LU1037948541.HKD","LU2237443549.SGD","IE00BJT1NW94.SGD","LU0203345920.USD","LU2237443895.HKD","BK4559","LU2133065610.SGD","SG9999015945.SGD","IE0009355771.USD","IE00BSNM7G36.USD","LU2237443382.USD","LU0058720904.USD","IE00BLSP4239.USD","LU0553294199.USD","LU2023251221.USD","LU1934455863.HKD","LU0965509283.SGD","LU0310800379.SGD","LU1093756325.SGD","LU1496350171.SGD","LU0859254822.USD","BK4566","LU0234570918.USD","LU1551013425.SGD","IE00BGHQF631.EUR","LU0965509101.SGD","LU2129689431.USD","LU2129689514.USD","IE00BN8TJ469.HKD","LU0170899867.USD","LU2087621335.USD","LU0949170772.SGD","LU0868494708.USD","LU1291159041.SGD","LU2468319806.SGD","IE000BZT7R73.USD","LU0198837287.USD","LU0256863902.USD","BK4581","IE00B4R5TH58.HKD","IE0000B7K699.USD","LU0256863811.USD","LU0861579265.USD","LU0203347892.USD","IE00B42XCP33.USD","LU0029864427.USD","IE00BFTCPJ56.SGD","LU0114720955.EUR","LU0234572021.USD","LU0912757837.SGD","LU0943347566.SGD","LU2129689605.HKD","LU0795875169.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190294448","title":"Rinvoq® (乌帕替尼) 在对首个TNF抑制剂应答不佳的类风湿关节炎患者头对头研究中，主要终点指标表现优于Humira® (阿达木单抗)","url":"https://stock-news.laohu8.com/highlight/detail?id=1190294448","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190294448?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:02","pubTimestamp":1777374131,"startTime":"0","endTime":"0","summary":"在一项针对首个肿瘤坏死因子(TNF)抑制剂治疗失败后的类风湿关节炎患者的头对头临床研究中，Rinvoq® (乌帕替尼) 在主要终点指标上表现出优于Humira® (阿达木单抗)的疗效。该研究结果凸显了乌帕替尼在此类患者群体中的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","IE0009355771.USD","LU0124676726.USD","LU1267930573.SGD","ABBV","LU0203347892.USD","LU2133065610.SGD","SG9999001440.SGD","IE000SO60NU8.SGD","LU0949170772.SGD","LU0868494708.USD","SG9999003800.SGD","SG9999011175.SGD","LU1093756325.SGD","SG9999015952.SGD","IE00BFTCPJ56.SGD","LU0820561818.USD","LU0985320562.USD","LU0820561909.HKD","IE00BDGV0183.EUR","LU0234570918.USD","IE0002270589.USD","LU2023251221.USD","LU2129689431.USD","LU0689472784.USD","LU0661504455.SGD","LU0456855351.SGD","IE000F7OJYX1.SGD","LU1732800096.USD","LU0417517546.SGD","LU2237443382.USD","LU1929549753.HKD","LU0029864427.USD","BK4588","BK4559","BK4550","LU0098860793.USD","LU2087621335.USD","LU1496350502.SGD","LU0553294199.USD","IE00B3PB1722.GBP","SG9999015978.USD","LU0738911758.USD","LU0965509101.SGD","LU1934455277.USD","LU1989772840.SGD","LU0965509010.AUD","LU1718418525.SGD","SG9999015986.USD","LU0708994859.HKD","LU0320765646.SGD","LU1037948541.HKD","LU2089984988.USD","LU1732799900.SGD","LU1934455863.HKD","LU2237443549.SGD","LU1983299246.USD","LU0069063385.USD","LU1551013342.USD","IE00BGHQF631.EUR","LU0859254822.USD","IE00B42XCP33.USD","LU0861579265.USD","LU0943347566.SGD","LU1244550577.SGD","LU0689626769.HKD","IE00BLSP4239.USD","LU0058720904.USD","LU0310799852.SGD","LU0868494617.USD","LU0289739343.SGD","LU1934455194.USD","BK4534","IE00BVYPNV92.GBP","LU0432979614.USD","LU0545039389.USD","IE000WAW04H5.SGD","LU1023059063.AUD","LU0128525929.USD","LU2237443465.HKD","LU2237443978.SGD","LU0234572021.USD","LU0472753341.HKD","LU1037948897.HKD","LU0198837287.USD","LU1003077747.HKD","LU1989772923.USD","IE00BJT1NW94.SGD","LU1162221912.USD","LU0203345920.USD","IE00BN8TJ469.HKD","LU1291159041.SGD","LU1839511570.USD","IE0000B7K699.USD","LU1057294990.SGD","LU0965508806.USD","LU0289961442.SGD","LU0310800379.SGD","LU0158827948.USD","LU0511384066.AUD","LU0965509283.SGD","LU2089283258.USD","LU1074936037.SGD","LU2129689514.USD","IE00BSNM7G36.USD","LU2237443895.HKD","LU1244550221.USD","SG9999015945.SGD","LU1093756168.USD","LU0211327993.USD","IE00BJJMRZ35.SGD","LU1496350171.SGD","IE0004445239.USD","LU2237443622.USD","LU0795875169.SGD","LU0795875086.SGD","LU0211328371.USD","LU1585245621.USD","LU2347655156.SGD","LU0057025933.USD","LU0170899867.USD","LU1244550494.USD","LU0942090050.USD","IE00B2B36J28.USD","LU2468319806.SGD","BK4566","BK4139","LU2112291526.USD","IE00BVYPNW00.USD","BK4585","IE000MB6IJN5.SGD","LU0122379950.USD","LU2129689605.HKD","IE0002141913.USD","BK4533","LU0882574055.USD","LU1061106388.HKD","LU1551013425.SGD","LU1989771016.USD","IE00B19Z3581.USD","LU2089284900.SGD","IE00B4R5TH58.HKD","LU0256863902.USD","LU0114720955.EUR","LU0256863811.USD","LU1430594728.SGD","IE000BZT7R73.USD","LU0289739699.SGD","LU0912757837.SGD","BK4581","LU2357627491.SGD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU1267930490.SGD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187354202","title":"艾伯维向FDA提交Skyrizi®用于中重度活动性克罗恩病成人患者皮下诱导治疗的监管申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1187354202","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187354202?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:18","pubTimestamp":1777292296,"startTime":"0","endTime":"0","summary":"生物制药巨头艾伯维公司已正式向美国食品药品监督管理局（FDA）提交监管申请，寻求批准其创新药物Skyrizi®（risankizumab-rzaa）用于中重度活动性克罗恩病成人患者的皮下诱导治疗方案。此次申请标志着该药物在拓展胃肠道疾病治疗适应症方面迈出关键一步，有望为克罗恩病患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1496350171.SGD","LU2089283258.USD","LU0545039389.USD","IE00BJT1NW94.SGD","LU0511384066.AUD","LU0310800379.SGD","LU2237443382.USD","LU1496350502.SGD","LU1551013342.USD","LU0310799852.SGD","LU0949170772.SGD","IE0004445239.USD","LU1983299246.USD","LU0965509283.SGD","LU0234572021.USD","IE000SO60NU8.SGD","IE00BLSP4452.SGD","LU0432979614.USD","LU0456855351.SGD","LU1093756168.USD","LU0661504455.SGD","LU0124676726.USD","BK4581","IE00B19Z3B42.SGD","LU0820561909.HKD","LU1989772840.SGD","LU0738911758.USD","LU0170899867.USD","LU0320765646.SGD","LU1057294990.SGD","LU1551013425.SGD","LU1093756325.SGD","BK4533","LU2087621335.USD","IE000BZT7R73.USD","LU0965509010.AUD","LU2089284900.SGD","SG9999015978.USD","LU0256863902.USD","LU2237443895.HKD","LU0868494617.USD","LU1074936037.SGD","LU2129689514.USD","BK4139","LU1162221912.USD","SG9999003800.SGD","LU0198837287.USD","LU2237443622.USD","LU0417517546.SGD","LU0128525929.USD","LU0057025933.USD","LU0472753341.HKD","IE000WAW04H5.SGD","IE00BVYPNV92.GBP","IE00BFTCPJ56.SGD","LU1430594728.SGD","LU0553294199.USD","IE00B42XCP33.USD","IE000F7OJYX1.SGD","LU0795875086.SGD","LU0823416689.USD","LU2468319806.SGD","IE00B3PB1722.GBP","LU0098860793.USD","LU1989771016.USD","SG9999001440.SGD","IE00BLSP4239.USD","LU1934455863.HKD","LU0203347892.USD","LU2129689431.USD","LU1839511570.USD","BK4588","LU1267930573.SGD","LU0069063385.USD","LU2133065610.SGD","LU0820561818.USD","LU1244550577.SGD","LU0211328371.USD","IE00BJJMRZ35.SGD","LU1037948897.HKD","LU2023251221.USD","IE0009355771.USD","LU0289739699.SGD","BK4534","IE00BSNM7G36.USD","LU0114720955.EUR","LU0942090050.USD","LU1585245621.USD","IE00BVYPNW00.USD","LU0058720904.USD","SG9999011175.SGD","LU0868494708.USD","LU0912757837.SGD","LU2112291526.USD","LU0122379950.USD","BK4566","LU0965509101.SGD","LU1003077747.HKD","ABBV","LU0029864427.USD","LU1244550221.USD","LU0689472784.USD","BK4550","LU0211327993.USD","LU1244550494.USD","LU2357627491.SGD","LU0708994859.HKD","LU0256863811.USD","LU0859254822.USD","IE0000B7K699.USD","LU1732799900.SGD","LU2347655156.SGD","LU1934455277.USD","LU0882574055.USD","SG9999015952.SGD","BK4559","IE00B19Z3581.USD","LU0965508806.USD","LU0289961442.SGD","IE00B2B36J28.USD","LU0289739343.SGD","LU0689626769.HKD","LU0861579265.USD","SG9999015945.SGD","LU1718418525.SGD","LU1037948541.HKD","IE00BN8TJ469.HKD","LU1291159041.SGD","LU2237443465.HKD","LU2237443549.SGD","LU1732800096.USD","IE00BBT3K403.USD","LU0158827948.USD","LU0985320562.USD","IE0002270589.USD","LU1023059063.AUD","LU1989772923.USD","LU2129689605.HKD","LU2237443978.SGD","LU0943347566.SGD","SG9999015986.USD","LU1267930490.SGD","LU1929549753.HKD","BK4585","LU2089984988.USD","IE0002141913.USD","IE00BGHQF631.EUR","LU0234570918.USD","IE00BDGV0183.EUR","LU0795875169.SGD","LU1934455194.USD","LU0203345920.USD","IE00B4R5TH58.HKD","IE000MB6IJN5.SGD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166311849","title":"财报前瞻｜艾伯维公司本季度营收预计增13.93%，机构观点偏空","url":"https://stock-news.laohu8.com/highlight/detail?id=1166311849","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166311849?lang=zh_cn&edition=full","pubTime":"2026-04-22 08:02","pubTimestamp":1776816149,"startTime":"0","endTime":"0","summary":"艾伯维公司计划于2026年04月29日美股盘前发布最新季度业绩，市场聚焦增长动能与利润弹性。上季度艾伯维公司实现营收166.18亿美元，同比增长10.04%；毛利率72.61%；归属于母公司股东的净利润18.16亿美元，净利率10.93%；调整后每股收益2.71美元，同比增长25.46%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜艾伯维公司本季度营收预计增13.93%，机构观点偏空","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABBV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137791418","title":"Collplant计划开发新型再生真皮与软组织填充剂产品组合，目标两年内启动临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1137791418","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137791418?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:03","pubTimestamp":1776078204,"startTime":"0","endTime":"0","summary":"Collplant公司近日宣布，将着手开发一系列创新的再生真皮与软组织填充剂新产品组合。该公司明确表示，计划在未来两年内正式启动相关临床实验，以验证其安全性与有效性。这一战略布局旨在拓展其在再生医学领域的产品管线，为市场带来更先进的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989771016.USD","LU0158827948.USD","LU0949170772.SGD","LU1244550221.USD","IE0002270589.USD","LU1551013425.SGD","LU1934455863.HKD","LU0234570918.USD","LU2089283258.USD","LU1989772840.SGD","LU0128525929.USD","ABBV","LU1839511570.USD","LU2237443895.HKD","LU2089284900.SGD","LU0795875169.SGD","LU1496350502.SGD","LU0417517546.SGD","LU0738911758.USD","LU1718418525.SGD","LU0882574055.USD","LU0170899867.USD","IE00B2B36J28.USD","LU0432979614.USD","LU1061106388.HKD","LU2237443382.USD","LU1551013342.USD","LU0689626769.HKD","LU0122379950.USD","LU0058720904.USD","LU0661504455.SGD","LU0912757837.SGD","LU0203345920.USD","LU0114720955.EUR","LU0708994859.HKD","LU2023251221.USD","LU1162221912.USD","LU0820561818.USD","LU0203347892.USD","LU0320765646.SGD","LU1989772923.USD","LU0943347566.SGD","LU0868494708.USD","LU1496350171.SGD","IE000F7OJYX1.SGD","LU1057294990.SGD","LU0211328371.USD","IE00BLSP4452.SGD","LU2129689514.USD","LU0965509283.SGD","LU2089984988.USD","SG9999015945.SGD","BK4139","LU2468319806.SGD","BK4581","IE00BN8TJ469.HKD","BK4566","LU1023059063.AUD","LU1003077747.HKD","LU2237443978.SGD","LU0198837287.USD","LU2112291526.USD","LU1732800096.USD","LU0553294199.USD","LU1430594728.SGD","IE000BZT7R73.USD","SG9999015986.USD","BK4533","IE00BJT1NW94.SGD","LU0289739699.SGD","LU0211327993.USD","LU1267930490.SGD","LU0029864427.USD","IE000SO60NU8.SGD","BK4534","IE00BDGV0183.EUR","LU0795875086.SGD","LU0456855351.SGD","IE00BBT3K403.USD","LU0861579265.USD","LU1732799900.SGD","LU1983299246.USD","LU0124676726.USD","LU0289739343.SGD","LU2237443549.SGD","LU0985320562.USD","LU0234572021.USD","LU0289961442.SGD","LU0820561909.HKD","IE0004445239.USD","LU0868494617.USD","IE00BGHQF631.EUR","BK4550","LU1037948897.HKD","IE00B3PB1722.GBP","LU0942090050.USD","LU0057025933.USD","LU1929549753.HKD","LU0472753341.HKD","LU2237443622.USD","LU2129689605.HKD","LU0310799852.SGD","IE00BSNM7G36.USD","SG9999001440.SGD","IE0000B7K699.USD","LU2129689431.USD","LU1037948541.HKD","LU1093756168.USD","SG9999011175.SGD","LU2347655156.SGD","BK4585","IE00BVYPNW00.USD","LU0310800379.SGD","IE000WAW04H5.SGD","LU0256863811.USD","LU0965509010.AUD","LU0069063385.USD","SG9999015952.SGD","IE00BLSP4239.USD","LU2133065610.SGD","IE00B19Z3B42.SGD","SG9999015978.USD","LU1934455277.USD","LU1244550494.USD","LU1093756325.SGD","BK4559","LU0965509101.SGD","LU2237443465.HKD","IE00BFTCPJ56.SGD","IE00B19Z3581.USD","LU0256863902.USD","LU0965508806.USD","LU1934455194.USD","LU0689472784.USD","LU1074936037.SGD","LU1267930573.SGD","IE00B42XCP33.USD","IE00BJJMRZ35.SGD","LU1244550577.SGD","LU1585245621.USD","IE000MB6IJN5.SGD","IE00BVYPNV92.GBP","LU0098860793.USD","LU1291159041.SGD","LU2087621335.USD","BK4588","IE00B4R5TH58.HKD","IE0002141913.USD","IE0009355771.USD","LU0511384066.AUD","LU0545039389.USD","SG9999003800.SGD","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139488426","title":"艾尔建工业公司行使权利终止与Collplant Biotechnologies Ltd的开发协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1139488426","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139488426?lang=zh_cn&edition=full","pubTime":"2026-04-13 19:03","pubTimestamp":1776078197,"startTime":"0","endTime":"0","summary":"艾尔建工业公司已正式行使其权利，终止了与Collplant Biotechnologies Ltd之间原有的开发合作协议。这一决定标志着双方在相关技术领域的合作暂时告一段落。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1929549753.HKD","IE00BLSP4239.USD","LU2129689605.HKD","LU2112291526.USD","LU0689472784.USD","IE00BFTCPJ56.SGD","LU0057025933.USD","IE0009355771.USD","IE00BBT3K403.USD","LU0320765646.SGD","SG9999015986.USD","LU1244550494.USD","LU0472753341.HKD","SG9999003800.SGD","LU0170899867.USD","LU0868494617.USD","LU1732799900.SGD","LU0795875169.SGD","LU1934455863.HKD","LU2237443382.USD","LU0820561909.HKD","LU0234572021.USD","LU0795875086.SGD","IE00B2B36J28.USD","LU0965509010.AUD","LU1267930573.SGD","LU0158827948.USD","LU2023251221.USD","LU2087621335.USD","LU0511384066.AUD","LU2089284900.SGD","LU0861579265.USD","IE000MB6IJN5.SGD","IE0004445239.USD","LU0942090050.USD","IE000BZT7R73.USD","LU0965508806.USD","ABBV","LU1291159041.SGD","LU0553294199.USD","LU1162221912.USD","LU1989772923.USD","LU1003077747.HKD","LU1093756168.USD","LU0029864427.USD","IE00BLSP4452.SGD","LU1989771016.USD","IE00BDGV0183.EUR","SG9999015952.SGD","LU2468319806.SGD","LU0912757837.SGD","LU0868494708.USD","LU1732800096.USD","LU2237443895.HKD","LU0058720904.USD","LU0198837287.USD","LU0689626769.HKD","LU1093756325.SGD","IE000WAW04H5.SGD","LU0211328371.USD","LU0456855351.SGD","LU0738911758.USD","IE000F7OJYX1.SGD","BK4566","IE00BN8TJ469.HKD","LU0203345920.USD","LU0820561818.USD","IE00BVYPNV92.GBP","LU0708994859.HKD","LU0965509283.SGD","IE000SO60NU8.SGD","LU2347655156.SGD","LU0882574055.USD","LU0234570918.USD","LU0124676726.USD","LU0965509101.SGD","BK4534","LU1430594728.SGD","LU0823416689.USD","LU1496350171.SGD","LU1551013342.USD","LU0211327993.USD","BK4139","LU0310799852.SGD","LU0098860793.USD","LU2237443549.SGD","LU1037948897.HKD","IE00BJT1NW94.SGD","LU2129689514.USD","LU0122379950.USD","LU0289961442.SGD","LU0114720955.EUR","IE00B42XCP33.USD","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LU1023059063.AUD","IE00B3PB1722.GBP","LU0432979614.USD","SG9999015945.SGD","BK4581","LU1244550577.SGD","SG9999015978.USD","IE0002141913.USD","LU1037948541.HKD","LU1983299246.USD","LU2237443465.HKD","BK4588","LU0128525929.USD","BK4559","LU2089283258.USD","IE00BVYPNW00.USD","LU0289739699.SGD","LU0203347892.USD","LU1585245621.USD","LU0545039389.USD","LU1267930490.SGD","IE00B4R5TH58.HKD","LU0985320562.USD","LU1934455277.USD","LU2129689431.USD","IE00BGHQF631.EUR","LU1074936037.SGD","LU1989772840.SGD","LU1718418525.SGD","LU2133065610.SGD","LU0256863811.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","LU2089984988.USD","LU2237443978.SGD","LU0943347566.SGD","SG9999011175.SGD","LU0310800379.SGD","LU0069063385.USD","LU1551013425.SGD","LU2237443622.USD","LU1934455194.USD","LU0417517546.SGD","LU1496350502.SGD","LU1839511570.USD","LU0256863902.USD","LU0949170772.SGD","BK4585","LU1244550221.USD","LU0661504455.SGD","IE0000B7K699.USD","IE0002270589.USD","LU1057294990.SGD","BK4533","SG9999001440.SGD","BK4550","LU0289739343.SGD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165970887","title":"海思科将获3000万美元首付款，潜在里程碑付款最高可达7.15亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165970887","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165970887?lang=zh_cn&edition=full","pubTime":"2026-04-12 16:12","pubTimestamp":1775981533,"startTime":"0","endTime":"0","summary":"海思科医药集团宣布，公司将获得3000万美元的首付款，并有资格获得最高达7.15亿美元的潜在里程碑付款。此次交易涉及与艾伯维公司的合作协议，标志着海思科在创新药研发领域的重大进展。根据协议条款，海思科将负责特定研发项目的推进，而艾伯维公司将基于项目进展支付相应款项。这一合作不仅为海思科带来即时的资金支持，还为其长期发展提供了重要的财务保障。业界认为，此类高额里程碑付款安排，凸显了海思科研发能力的国际认可度，有望进一步提升其在全球医药市场的竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2237443465.HKD","LU1718418525.SGD","IE000WAW04H5.SGD","LU2237443978.SGD","SG9999011175.SGD","LU1093756168.USD","LU1934455194.USD","LU1496350171.SGD","BK4585","LU0949170772.SGD","LU2237443382.USD","LU0985320562.USD","LU1267930573.SGD","IE00BBT3K403.USD","BK4566","SG9999015978.USD","LU0820561818.USD","IE00BGHQF631.EUR","LU0158827948.USD","IE000MB6IJN5.SGD","LU0661504455.SGD","LU1551013425.SGD","LU0417517546.SGD","LU0234572021.USD","ABBV","IE00B19Z3B42.SGD","LU2129689605.HKD","002653","LU2237443895.HKD","IE00BFTCPJ56.SGD","LU1496350502.SGD","LU0965509010.AUD","BK4533","LU0124676726.USD","LU0198837287.USD","LU2089984988.USD","IE0002270589.USD","LU0795875169.SGD","LU0098860793.USD","LU0882574055.USD","LU1929549753.HKD","LU0942090050.USD","LU0211327993.USD","SG9999015945.SGD","LU0553294199.USD","LU1430594728.SGD","BK0077","IE0004445239.USD","LU0432979614.USD","LU2089283258.USD","LU2133065610.SGD","LU0203347892.USD","IE00BVYPNV92.GBP","BK0188","LU0234570918.USD","LU0289961442.SGD","LU0795875086.SGD","LU0965509101.SGD","LU0320765646.SGD","LU1291159041.SGD","BK4581","BK0028","LU0823416689.USD","LU0289739343.SGD","IE000SO60NU8.SGD","IE00B4R5TH58.HKD","LU2023251221.USD","SG9999003800.SGD","BK0239","LU0738911758.USD","SG9999001440.SGD","LU1732800096.USD","LU0256863811.USD","LU1074936037.SGD","LU0820561909.HKD","LU0170899867.USD","LU2112291526.USD","LU1989772923.USD","IE000F7OJYX1.SGD","LU0912757837.SGD","BK4534","BK4559","IE000BZT7R73.USD","LU1839511570.USD","LU0310799852.SGD","LU2237443549.SGD","LU1934455277.USD","LU0868494708.USD","LU1551013342.USD","IE00BLSP4452.SGD","BK4550","LU1061106388.HKD","LU2468319806.SGD","LU1003077747.HKD","LU1244550577.SGD","LU0069063385.USD","LU2089284900.SGD","LU2129689431.USD","LU1037948541.HKD","LU1244550221.USD","LU1983299246.USD","LU1934455863.HKD","LU1244550494.USD","LU1093756325.SGD","LU0545039389.USD","LU0122379950.USD","LU0058720904.USD","LU1732799900.SGD","LU1267930490.SGD","LU2129689514.USD","LU0310800379.SGD","LU0689626769.HKD","LU0708994859.HKD","LU2237443622.USD","SG9999015952.SGD","BK4139","IE0009355771.USD","LU0689472784.USD","IE00BLSP4239.USD","LU0211328371.USD","LU1057294990.SGD","LU1162221912.USD","IE0002141913.USD","IE00B3PB1722.GBP","IE00BSNM7G36.USD","LU2347655156.SGD","IE00BJT1NW94.SGD","LU0114720955.EUR","LU0029864427.USD","BK0033","IE00B2B36J28.USD","LU0943347566.SGD","LU0256863902.USD","LU0203345920.USD","LU1989772840.SGD","LU1989771016.USD","IE00BVYPNW00.USD","LU1037948897.HKD","LU0868494617.USD","SG9999015986.USD","LU0861579265.USD","LU2087621335.USD","IE00B19Z3581.USD","IE00BDGV0183.EUR","LU0965508806.USD","LU1023059063.AUD","LU0472753341.HKD","LU0965509283.SGD","LU0289739699.SGD","LU0456855351.SGD","LU0511384066.AUD","IE00BJJMRZ35.SGD","IE0000B7K699.USD","IE00BN8TJ469.HKD","LU0057025933.USD","IE00B42XCP33.USD","LU0128525929.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":0.0437},{"period":"1month","weight":0.1083},{"period":"3month","weight":-0.0125},{"period":"6month","weight":0.0051},{"period":"1year","weight":0.2121},{"period":"ytd","weight":-0.0055}],"compareEarnings":[{"period":"1week","weight":-0.025},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.0969},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.2437},{"period":"ytd","weight":0.0816}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日，是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法，来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域，包括类风湿性关节炎，牛皮癣和克罗恩病，银屑病和克罗恩病;低睾酮，HIV，子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.357143,"avgChangeRate":-0.019222},{"month":2,"riseRate":0.857143,"avgChangeRate":0.039081},{"month":3,"riseRate":0.714286,"avgChangeRate":0.001102},{"month":4,"riseRate":0.571429,"avgChangeRate":0.006536},{"month":5,"riseRate":0.642857,"avgChangeRate":0.004172},{"month":6,"riseRate":0.5,"avgChangeRate":0.01128},{"month":7,"riseRate":0.538462,"avgChangeRate":0.01232},{"month":8,"riseRate":0.538462,"avgChangeRate":0.007409},{"month":9,"riseRate":0.538462,"avgChangeRate":0.014941},{"month":10,"riseRate":0.615385,"avgChangeRate":0.007438},{"month":11,"riseRate":0.769231,"avgChangeRate":0.063841},{"month":12,"riseRate":0.692308,"avgChangeRate":0.025718}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}